DSIP

$35.00
QUANTITY
1
BUNDLE & SAVE
Total (1 Vial)

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide studied for its influence on sleep architecture, particularly delta-wave (deep) sleep regulation. Research also explores its role in modulating the stress-response system, cortisol regulation, and overall recovery processes. As a compound of interest in neuroscience and recovery-focused research, DSIP is manufactured to strict quality standards and verified through third-party lab testing (COA available on request).

For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

Product Description

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide studied for its influence on sleep architecture, particularly delta-wave (deep) sleep regulation. Research also explores its role in modulating the stress-response system, cortisol regulation, and overall recovery processes. As a compound of interest in neuroscience and recovery-focused research, DSIP is manufactured to strict quality standards and verified through third-party lab testing (COA available on request).

For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

Compound Information
MOLECULAR PROFILE
TypeSynthetic compound
CategoryResearch Compound
Purity≥99%
FormLyophilized powder
STORAGE REQUIREMENTS
Lyophilized (powder)

-20°C · 24+ months

Reconstituted

2–8°C · ~30 days

Certificate of Analysis

Third-party tested for purity and quality.

PURITY
0 %
Variant GLP3-RT 10mg
Lot # REF0001
Labeled 20mg
Actual 22.61mg
Tested APR 15, 2026

Coming soon

Research
New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

Related Research

Free shipping

on orders over $200

Discreet shipping

plain and unbranded packaging

Secure checkout

256-bit SSL

Researcher verification.
Lightning Peptides LLC sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration.

Not a researcher? Exit